Company: Achaogen
Based: South San Francisco
Amount: $56.31M

Investors: Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and the Wellcome Trust

Scoop: Last spring, 2009 Fierce 15 company Achaogen announced that it had raised $56 million in a Series C round of financing. New investors Frazier Healthcare Ventures and Alta Partners joined a syndicate of previous investors in the round.

"Our mission is to discover and develop life-saving antibiotics," CEO Kevin Judice (photo) said at the time. "This financing together with non-dilutive capital that we have secured through partnerships with various government agencies will enable us to advance multiple clinical programs, including conducting a Phase II study in complicated urinary tract infections of ACHN-490, our lead candidate for multi-drug resistant bacterial infections."

Related Articles:
Achaogen wins $64M biodefense contract
Achaogen: Top 5 Biotech VC Deals, H1 2010
Flush with cash, Achaogen continues antibiotic work
Achaogen raises $56M for antibiotic work